Using targeted immune cells to treat brain lymphoma
Official title: Intracerebroventricular (ICV) Administration of CD19-Targeting Chimeric Antigen Receptor (CAR) T cells for Treatment of Primary Central Nervous System Lymphoma
Funded at Beckman Research Institute/city of Hope · NIH-10912468 · Data updated 2026-11-12
This study is testing a new way to treat primary central nervous system lymphoma by delivering special immune cells directly into the brain to help them better fight the cancer, and it's designed for patients looking for more effective options than what's currently available.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Beckman Research Institute/city of Hope NIH-funded |
| Lab location | 1 site (Duarte, United States) |
| Project start | September 9, 2022 |
| Project end | August 31, 2028 |
| Funding year | 2024 |
| Award (this year) | $364,612 |
| NIH project number | 5R01CA266611-03 |
| Project ID | NIH-10912468 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with primary central nervous system lymphoma who have not responded adequately to standard treatments.
✕Less likely to help
Patients with other types of lymphoma or those who do not have central nervous system involvement may not benefit from this research.
What this research studies
This research investigates a new approach to treating primary central nervous system lymphoma (PCNSL) by administering CD19-targeting chimeric antigen receptor (CAR) T cells directly into the brain's ventricles. The goal is to enhance the effectiveness of these immune cells in attacking lymphoma cells that are difficult to reach with traditional intravenous methods. By focusing on locoregional delivery, the study aims to improve patient outcomes compared to existing treatments that have not changed in decades. Patients will be monitored for safety and efficacy as the treatment progresses.
Why it matters
Potential benefit: If successful, this research could provide a more effective treatment option for patients with primary central nervous system lymphoma, potentially leading to better survival rates.
How similar studies have gone: Previous studies have shown success with locoregional delivery of CAR T cells in treating other central nervous system malignancies, suggesting a promising avenue for this approach.
Where this research is happening
-
Beckman Research Institute/city of Hope
Duarte, United States Active
Researchers
- Principal investigator: Wang, Xiuli — Beckman Research Institute/city of Hope
- Study coordinator: Wang, Xiuli
Related research
Other NIH-funded projects on the same topics.
-
Direct-to-CNS CAR T cells for PCNSL treatment
A patient-focused look at using CD19 CAR T cells delivered directly into the brain to treat primary CNS lymphoma.
-
CD19 CAR T cells given into the brain fluid for primary CNS lymphoma
This work uses CD19-directed CAR T cells delivered into the fluid around the brain to treat people with primary central nervous system lymphoma.
-
Understanding why Black and Hispanic Hodgkin lymphoma patients have worse survival
A patient-centered study to uncover social and care factors that contribute to lower survival among Black and Hispanic people with Hodgkin lymphoma across all ages.
-
Preventing follicular lymphoma progression with precision therapy
This grant tests a targeted approach to stop follicular lymphoma from getting worse or turning into a more aggressive cancer.
-
Novel combination therapy for non-Hodgkin lymphoma in people and dogs
A new treatment combo using an oncolytic virus and other therapies is being tested to help people with hard-to-treat non-Hodgkin lymphoma, with studies also involving dogs to better understand responses.
-
Cyclin D1 and DNA Repair in Mantle Cell Lymphoma: A Path to New Therapies
A clinician-researcher at Mayo Clinic is pursuing advanced training and research to understand how Cyclin D1 drives replication stress and to explore new targeted treatments for high-risk mantle cell lymphoma.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.